Journal articles on the topic 'Equity lines'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Equity lines.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
ANNAOUI, Ilias, and Pascal BARNETO. "The Determinants of Equity Lines Financing: An International Study." Bankers, Markets & Investors 171, no. 3 (December 22, 2022): 43–50. http://dx.doi.org/10.54695/bmi.171.8461.
Ebens, Allen J., Leanne Berry, Yung-Hsiang Chen, Gauri Deshmukh, Jake Drummond, Changchun Du, Michael Eby, et al. "A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: The Biology of Single Agent and PI3K/AKT/mTOR Combination Activity." Blood 116, no. 21 (November 19, 2010): 3001. http://dx.doi.org/10.1182/blood.v116.21.3001.3001.
Annaoui, Ilias, and Pascal Barneto. "Mécanismes de gouvernance et financement par Equity lines." Management & Avenir N° 135, no. 3 (June 6, 2023): 37–60. http://dx.doi.org/10.3917/mav.135.0037.
Ngo, Anh, Oscar Varela, and Xie Feixue. "The effects of lines of credit on market timing and the underpricing of seasoned equity offerings." Review of Accounting and Finance 18, no. 1 (February 11, 2019): 157–75. http://dx.doi.org/10.1108/raf-09-2016-0153.
Thomenius, Michael J., Jennifer Totman, Kat Cosmopoulos, Dorothy Brach, Lei Ci, Neil Farrow, Jesse J. Smith, et al. "Identification of a First-in-Class SETD2 Inhibitor That Shows Potent and Selective Anti-Proliferative Activity in t(4;14) Multiple Myeloma: T(4;14) Multiple Myeloma Cells Are Dependent on Both H3K36 Di and Tri-Methylation." Blood 132, Supplement 1 (November 29, 2018): 3207. http://dx.doi.org/10.1182/blood-2018-99-110803.
Munugalavadla, Veerendra, Leanne Berry, Yung-Hsiang Chen, Gauri Deshmukh, Jake Drummond, Changchun Du, Michael Eby, et al. "A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: Mechanism of Action and Signal Transduction Studies." Blood 116, no. 21 (November 19, 2010): 4084. http://dx.doi.org/10.1182/blood.v116.21.4084.4084.
Dornan, David, Bart Burington, Peng Yue, Xiaoyan Shi, Ranjana Advani, Nancy Yu, Jeffrey T. Lau, et al. "CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma." Blood 114, no. 22 (November 20, 2009): 2721. http://dx.doi.org/10.1182/blood.v114.22.2721.2721.
SALANDRO, DAN, and WILLIAM B. HARRISON. "Determinants of the Demand for Home Equity Credit Lines." Journal of Consumer Affairs 31, no. 2 (December 1997): 326–45. http://dx.doi.org/10.1111/j.1745-6606.1997.tb00394.x.
Liu, Yang, and J. Jimmy Yang. "Private debt, unused credit lines, and seasoned equity offerings." Quarterly Review of Economics and Finance 51, no. 4 (November 2011): 376–88. http://dx.doi.org/10.1016/j.qref.2011.07.006.
Nadelson, Louis S., Rachelle G. Miller, Helen Hu, Na Mi Bang, and Brandy Walthall. "Is Equity on Their Mind? Documenting Teachers’ Education Equity Mindset." World Journal of Education 9, no. 5 (October 17, 2019): 26. http://dx.doi.org/10.5430/wje.v9n5p26.
Eastman, Stephen, Christopher Shelton, Ira Gupta, Julie Krueger, Christina Blackwell, and Paul M. Bojczuk. "Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines." Blood 134, Supplement_1 (November 13, 2019): 4401. http://dx.doi.org/10.1182/blood-2019-123705.
Ulanet, Danielle, Victor Chubukov, John Coco, Gabrielle McDonald, Mya Steadman, Rohini Narayanaswamy, Sebastien Ronseaux, et al. "Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials." Blood 134, Supplement_1 (November 13, 2019): 1570. http://dx.doi.org/10.1182/blood-2019-123471.
Sampath, Deepak, Elizabeth Punnoose, Erwin R. Boghaert, Lisa Belmont, Jun Chen, Franklin Peale, Nguyen Tan, et al. "Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models." Blood 120, no. 21 (November 16, 2012): 5028. http://dx.doi.org/10.1182/blood.v120.21.5028.5028.
Erickson-Miller, Connie L., Jennifer Kirchner, Kodandaram Pillarisetti, Lone Ottesen, Yasser Mostafa Kamel, Yuan Liu, Anne-Marie Martin, and Conrad Messam. "Eltrombopag Decreases Proliferation of Ovarian, Lung and Breast Tumor Cell Lines." Blood 114, no. 22 (November 20, 2009): 2409. http://dx.doi.org/10.1182/blood.v114.22.2409.2409.
Pramanik, Anik, Pan Xu, and Yifan Xu. "Equity Promotion in Public Transportation." Proceedings of the AAAI Conference on Artificial Intelligence 37, no. 10 (June 26, 2023): 11890–98. http://dx.doi.org/10.1609/aaai.v37i10.26403.
Maira Muniz Almeida, Wanda, and Eliane Guaraldo. "Urban Green Equity." Life Style 8, no. 2 (June 2, 2022): 64–74. http://dx.doi.org/10.19141/2237-3756.lifestyle.v8.n2.p64-74.
Prabhu, Varun V., Rohinton S. Tarapore, Mathew J. Garnett, Ultan McDermott, Cyril H. Benes, Jessica M. Wagner, Wafik S. El-Deiry, Martin Stogniew, Wolfgang Oster, and Joshua E. Allen. "Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds." Blood 128, no. 22 (December 2, 2016): 5133. http://dx.doi.org/10.1182/blood.v128.22.5133.5133.
Thakurta, Anjan, Anita K. Gandhi, Michelle Waldman, Chad C. Bjorklund, Suzanne Lentzsch, Stephen A. Schey, Yolanda Calle, et al. "Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance." Blood 122, no. 21 (November 15, 2013): 3139. http://dx.doi.org/10.1182/blood.v122.21.3139.3139.
Arora, Shilpi, Kaylyn Williamson, Shruti Apte, Srividya Balachander, Jennifer Busby, Charlie Hatton, Barbara Bryant, and Patrick Trojer. "EZH2 Inhibitors Are Broadly Efficacious in Multiple Myeloma As Single Agent and in Combination with Standard of Care Therapeutics." Blood 128, no. 22 (December 2, 2016): 5672. http://dx.doi.org/10.1182/blood.v128.22.5672.5672.
Wang, Xiaomin, and Wenxin Zhang. "Efficiency and Spatial Equity Impacts of High-Speed Rail on the Central Plains Economic Region of China." Sustainability 11, no. 9 (May 5, 2019): 2583. http://dx.doi.org/10.3390/su11092583.
Ahsan, Aarif, Ann Polonskaia, Chih-Chao Hsu, Chad C. Bjorklund, Maria Ortiz Estevez, Fadi Towfic, Nizar J. Bahlis, et al. "Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination." Blood 138, Supplement 1 (November 5, 2021): 2658. http://dx.doi.org/10.1182/blood-2021-150641.
Chen, Janice, Christopher L. Brooks, Peter McDonald, Jonathan D. Schwartz, Rebecca S. Schneider, Keiichi Sakakibara, Naoya Saito, Takuji Sato, Takumi Kawabe, and Eric K. Rowinsky. "SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity." Blood 126, no. 23 (December 3, 2015): 4433. http://dx.doi.org/10.1182/blood.v126.23.4433.4433.
Liu, Yang. "The Sources of Debt Matter Too." Journal of Financial and Quantitative Analysis 41, no. 2 (June 2006): 295–316. http://dx.doi.org/10.1017/s0022109000002076.
Peng, Mao Yu, Yasmin Abaza, Martina Mcdermott, Monica Mead, Dennis J. Slamon, and Sarah Larson. "Activity of Carfilzomib (CFZ) in Acute Myeloid Leukemia (AML) As a Single Agent and in Novel Combinations." Blood 136, Supplement 1 (November 5, 2020): 6–7. http://dx.doi.org/10.1182/blood-2020-141459.
Zhang, Yue, Julie Parmentier, Zhongwu Lai, Greg O'Connor, Melissa Passino, Francoise Powell, Erik Devereaux, and Kate Byth. "Spleen Tyrosine Kinase Inhibitor Fostamatinib Blocks B Cell Receptor Signaling and Reduces Viability of BCR Subtype Diffuse Large B Cell Lymphoma." Blood 120, no. 21 (November 16, 2012): 3720. http://dx.doi.org/10.1182/blood.v120.21.3720.3720.
Fernández, Leonor, and Peter Shorett. "Lessons in Equity From the Front Lines of COVID-19 Vaccination." JAMA Health Forum 2, no. 4 (April 7, 2021): e210612. http://dx.doi.org/10.1001/jamahealthforum.2021.0612.
Turner, PG. "Fault Lines In Equity Edited by Jamie Glister and Pauline Ridge." Oxford University Commonwealth Law Journal 12, no. 2 (March 27, 2012): 393–97. http://dx.doi.org/10.1080/14729342.2012.11421351.
Gandhi, Anita K., Herve Avet-Loiseau, Michelle Waldman, Anjan Thakurta, Sharon L. Aukerman, Gengxin Chen, Derek Mendy, et al. "Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells." Blood 120, no. 21 (November 16, 2012): 4043. http://dx.doi.org/10.1182/blood.v120.21.4043.4043.
Lopez-Girona, Antonia, Courtney G. Havens, Gang Lu, Emily Rychak, Derek Mendy, Bonny Gaffney, Christine Surka, et al. "CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells." Blood 134, Supplement_1 (November 13, 2019): 1812. http://dx.doi.org/10.1182/blood-2019-124338.
Lyons, Torrey, and Dong-ah Choi. "Transit Economic Equity Index: Developing a Comprehensive Measure of Transit Service Equity." Transportation Research Record: Journal of the Transportation Research Board 2675, no. 3 (January 7, 2021): 288–300. http://dx.doi.org/10.1177/0361198120970529.
Rivera, Victor M., Justin R. Pritchard, Francois Gonzalvez, Theresa Baker, Joseph M. Gozgit, and Graeme Hodgson. "Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events." Blood 124, no. 21 (December 6, 2014): 1783. http://dx.doi.org/10.1182/blood.v124.21.1783.1783.
Li, Lingna, Wenyong Tong, Megan Lau, Katherine Fells, Tong Zhu, Yingqing Sun, Ernest Kovacs, et al. "Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies." Blood 134, Supplement_1 (November 13, 2019): 5621. http://dx.doi.org/10.1182/blood-2019-132062.
Wang, Beatrice T., Thomas J. Matthew, Ling Wang, Tasnim Kothambawala, Susan E. Calhoun, Eric W. Humke, Angus M. Sinclair, and Bruce A. Keyt. "The Anti-Tumor Activity of Igm-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, Is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML." Blood 136, Supplement 1 (November 5, 2020): 43–44. http://dx.doi.org/10.1182/blood-2020-141449.
Bates, Jamie, Saritha Kusam, Stacey Tannheimer, Astrid Clarke, Thomas Kenney, David Breckenridge, and Daniel Tumas. "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines." Blood 128, no. 22 (December 2, 2016): 5104. http://dx.doi.org/10.1182/blood.v128.22.5104.5104.
Cojocari, Dan, Sha Jin, Julie J. Purkal, Relja Popovic, Nari N. Talaty, Yu Xiao, Larry R. Solomon, Erwin Boghaert, Joel D. Leverson, and Darren C. Phillips. "5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis." Blood 132, Supplement 1 (November 29, 2018): 2644. http://dx.doi.org/10.1182/blood-2018-99-111985.
Pinho, Pedro, Helen Kylefjord, Vilma Rraklli, Christina Rydergård, Biljana Rizoska, Anders Eneroth, Johan Bylund, et al. "Protides of 5-Fluorotroxacitabine Display Potent Anti-Proliferative Properties and Circumvent Deoxycytidine Kinase-Mediated Resistance Associated with Cytotoxic Cytidine Analogues; A Novel Approach for Acute Myeloid Leukemia." Blood 132, Supplement 1 (November 29, 2018): 3497. http://dx.doi.org/10.1182/blood-2018-99-114440.
Klatt, Martin G., Zhiyuan Yang, Jianying Liu, Tatyana Korontsvit, Sung Soo Mun, Leila Peraro, Thomas J. Gardner, et al. "A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies." Blood 136, Supplement 1 (November 5, 2020): 20–21. http://dx.doi.org/10.1182/blood-2020-140179.
Totman, Jennifer, Dorothy Brach, Vinny Motwani, Selene Howe, Emily Deutschman, John Lampe, Thomas V. Riera, et al. "Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma." Blood 138, Supplement 1 (November 5, 2021): 1142. http://dx.doi.org/10.1182/blood-2021-151147.
Cheung, Kam, Gloria Juan, William Wayne, Kelly Hanestad, Kathleen Keegan, Justin Huard, Patricia McElroy, et al. "AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo." Blood 122, no. 21 (November 15, 2013): 3823. http://dx.doi.org/10.1182/blood.v122.21.3823.3823.
Chen, Jun, Sha Jin, Paul Tapang, Stephen K. Tahir, Morey Smith, John Xue, Haichao Zhang, et al. "CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1." Blood 124, no. 21 (December 6, 2014): 2161. http://dx.doi.org/10.1182/blood.v124.21.2161.2161.
Penebre, Elayne, Kristy G. Kuplast, Christina R. Majer, L. Danielle Johnston, Nathalie Rioux, Michael Munchhof, Lei Jin, et al. "Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma." Blood 124, no. 21 (December 6, 2014): 438. http://dx.doi.org/10.1182/blood.v124.21.438.438.
Weyland, Kurt. "“Growth With Equity” in Chile's New Democracy?" Latin American Research Review 32, no. 1 (1997): 37–68. http://dx.doi.org/10.1017/s0023879100037651.
Rychak, Emily, Derek Mendy, Karen Miller, Jim Leisten, Rama Krishna Narla, Heather K. Raymon, Rajesh Chopra, and Antonia Lopez-Girona. "The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide." Blood 122, no. 21 (November 15, 2013): 3160. http://dx.doi.org/10.1182/blood.v122.21.3160.3160.
McElligott, David L., Edward Kesicki, Kannan Karukarichi, Hyeseok Shim, Rui Wang, Albert S. Yu, Parisa Zolfaghari, et al. "Development of Inhibitors of PIP4K2 As a Treatment for Patients with Hematologic Malignancies." Blood 132, Supplement 1 (November 29, 2018): 213. http://dx.doi.org/10.1182/blood-2018-99-118355.
Csibi, Fred, Nan Ji, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, Scott Rusin, et al. "Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies." Blood 134, Supplement_1 (November 13, 2019): 3803. http://dx.doi.org/10.1182/blood-2019-128981.
Ding, Bei Bei, John Dixon Gray, Irina Krapf, Yanliang Zhang, Nan Zhang, Qingdong Mark Deng, Angel Wei, et al. "Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure." Blood 134, Supplement_1 (November 13, 2019): 4444. http://dx.doi.org/10.1182/blood-2019-131586.
Fiore, Christopher, Michael R. McKeown, Emily Lee, Matthew L. Eaton, and Christian C. Fritz. "SY1425 (tamibarotene) Induces Profound Transcriptional Changes in AML Tumors with High Retinoic Acid Receptor Alpha." Blood 128, no. 22 (December 2, 2016): 1523. http://dx.doi.org/10.1182/blood.v128.22.1523.1523.
Lowe, Eric, Andrea R. Fan, Jing Jiang, Henry W. B. Johnson, Christopher J. Kirk, Dustin McMinn, Tony Muchamuel, Yu Qian, and Brian B. Tuch. "Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies." Blood 134, Supplement_1 (November 13, 2019): 408. http://dx.doi.org/10.1182/blood-2019-123782.
Yang, Jun, Andong Guo, Xueming Li, and Tai Huang. "Study of the Impact of a High-Speed Railway Opening on China’s Accessibility Pattern and Spatial Equality." Sustainability 10, no. 8 (August 19, 2018): 2943. http://dx.doi.org/10.3390/su10082943.
Aryal, Neeraj K., Anjana Sundarrajan, Scott Boiko, David Jenkins, Huayang Liu, Miika Ahdesmaki, Aurelie Bornot, et al. "Elongator Complex Regulates MCL1 Dependency Via IRE1-XBP1 Axis of the ER Stress Response Pathway in Multiple Myeloma." Blood 138, Supplement 1 (November 5, 2021): 2275. http://dx.doi.org/10.1182/blood-2021-151194.